Recognition and Publications
Chao HJ, Walsh CE. RNA repair for haemophilia A. Expert Rev Mol Med. 2006 Jan 10;8(1):1-8.
Chao HJ, Walsh CE. AAV vectors for hemophilia B gene therapy. Mt Sinai J Med. 2004 Oct;71(5):305-13. Review.
Mansfield SG, Chao HJ, Walsh CE. RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol Med. 2004 Jun;10(6):263-8. Review.
Chao HJ, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003 Aug;9(8):1015-9. Epub 2003 Jul 6.
Chao HJ, Walsh CE. Hemophilia gene therapy: novel rAAV vectors and RNA repair strategy. Curr Opin Mol Ther. 2002 Oct;4(5):499-504. Review.
Chao HJ, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther. 2002 Jun;5(6):716-22.
Walsh CE, Chao HJ. Parvovirus-mediated gene transfer for the haemophilias. Haemophilia. 2002 Mar;8 Suppl 2:60-7. Review.
Chao HJ, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001 Sep;4(3):217-22.
Chao HJ, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood. 2001 May 15;97(10):3311-2.
Chao HJ, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000 Dec;2(6):619-23.
Chao HJ, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000 Mar 1;95(5):1594-9.
Chao HJ, Walsh CE. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine. Thromb Haemost. 1999 Oct;82(4):1378.
Chao HJ, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther. 1999 Oct;6(10):1695-704.
